Nichol Martinuik
Presidente presso ADORBS INC.
Posizioni attive di Nichol Martinuik
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ADORBS INC. | Presidente | 13/03/2023 | - |
| Presidente | 13/03/2023 | - | |
| Segretario Aziendale | 13/03/2023 | - | |
Myspray Therapeutics, Inc.
 Myspray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Adorbs, Inc., Myspray Therapeutics, Inc. is a Canadian company that develops natural health products for professional results. The company is based in Canora, Canada. Myspray's products are clinically developed, licensed, and manufactured to ensure potency, quality, and safety. The company's flagship product, myshrooms, contains a potency of 40%% polysaccharides from sustainably farmed organic sources and is tested to be pure USP medicinal grade. The company was founded in 2012 by Nichol Martinuik, and Rachel Martinuik has been the CEO of the company since 2012. Myspray Therapeutics was acquired by Adorbs, Inc. on February 10, 2022 for $30.67 million. | Direttore/Membro del Consiglio | 01/01/2012 | - |
| Fondatore | 01/01/2012 | - | |
| Presidente | 01/01/2012 | - |
Storia della carriera di Nichol Martinuik
Statistiche
Distribuzione geografica
| Canada | 3 |
Posizioni
| President | 2 |
| Director/Board Member | 1 |
| Founder | 1 |
Settori
| Consumer Non-Durables | 2 |
| Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ADORBS INC. | Consumer Non-Durables |
| Aziende private | 1 |
|---|---|
Myspray Therapeutics, Inc.
Myspray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Adorbs, Inc., Myspray Therapeutics, Inc. is a Canadian company that develops natural health products for professional results. The company is based in Canora, Canada. Myspray's products are clinically developed, licensed, and manufactured to ensure potency, quality, and safety. The company's flagship product, myshrooms, contains a potency of 40%% polysaccharides from sustainably farmed organic sources and is tested to be pure USP medicinal grade. The company was founded in 2012 by Nichol Martinuik, and Rachel Martinuik has been the CEO of the company since 2012. Myspray Therapeutics was acquired by Adorbs, Inc. on February 10, 2022 for $30.67 million. | Commercial Services |
- Borsa valori
- Insiders
- Nichol Martinuik
- Esperienza
